C. Goh, S. K. Ng
Sep 1, 1984
Citations
0
Influential Citations
33
Citations
Quality indicators
Journal
Contact Dermatitis
Abstract
Ranitidine HCI (Zantac®) is a commonly used H2 antagonist for the treatment of peptic ulcer. The manufacturing process involves 5 stages where various intermediate compounds are produced. Stage I results in the synthesis of amino alcohol; stage 2, a diamine liquid 5-[(2-aminoethyl)thiomethyl]-N, N-dimethyl2-furanmethanamine; stage 3, Ranitidine base; stage 4, Ranitidine HCI; stage 5 is a granulation process to form Ranitidine HCI granules. The whole procedure is carried out in a nearly totally closed system of reactors, but at various stages intermediate chemicals have to be poured into hatches of the reaction tanks, with the workers wearing special protective suites. The diamine liquid, 5-[(2-aminoethyl) thiomethyl] -N,N-dimethyl-2-furanmethanamine, encountered in stage 2 appeared to be a potent skin sensitizer (I). There has been no report of allergic contact dermatitis to Ranitidine, although urticaria from ingested Ranitidine HCI (2) and contact dermatitis to other H2 antagonists (3) have been reported. We report here a patient who developed allergic contact dermatitis to Ranitidine base. He was found to be sensitive to the diamine liquid too.